Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-11101 vs Darbepoetin Alfa in ND-CKD Anemia
NCT03431623Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2015
- Primary completion
- Feb 2017
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of Nesbell in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Changed amount of mean hemoglobin level in evaluation period compared to the baseline and Mean administration dose in evaluation period. Started May 2015; status: completed.
02
Drugs
Nesbell
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03431623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431623.